IQVIA HOLDINGS INC. 10-K

Item 9A. Controls and Procedures Evaluation of Disclosure Controls and Procedures As required by Rule 13a-15 under the Exchange Act, as amended, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures under the supervision and with the participation of our management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon our evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act, as amended, is recorded, processed, summarized and reported within the time periods specified in the applicable rules and forms, and that it is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Management’s Report on Internal Control over Financial Reporting Our management’s report on internal control over financial reporting is set forth in Part II, Item 8 of this Annual Report on Form 10-K and is incorporated herein by reference. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting during the quarter ended December 31, 2025 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Item 9B. Other Information During the quarter ended December 31, 2025, no director or officer (as defined in Exchange Act Rule 16a-1(f)) of IQVIA Holdings Inc. adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement for the purchase or sale of securities of IQVIA Holdings Inc., within the meaning of Item 408 of Regulation S-K. Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections Not applicable. 116 PART III Item 10. Directors, Executive Officers and Corporate Governance Information required by this Item, other than the information regarding the executive officers of the Company set forth below, is incorporated by reference to the sections of our definitive Proxy Statement for our 2026 Annual Meeting of Stockholders (the “2026 Proxy Statement”) entitled “Proposal No. 1: Election of Directors”, “Corporate Governance—Documents Establishing our Corporate Governance”, “Corporate Governance—Leadership Structure—Committees of the Board”, "Compensation Discussion and Analysis—Rigorous Accountability, Risk-Mitigation and Recovery Provisions—Insider Trading Policies and Procedures” and “Other Relevant Information—Delinquent Section 16(a) Reports.” The current executive officers of the Company are as follows: Name Age Position Ari Bousbib 64 Chairman and Chief Executive Officer Ronald E. Bruehlman 65 Executive Vice President and Chief Financial Officer W. Richard Staub, III 63 President, Research & Development Solutions Bhavik Patel 46 President, MedTech and Consumer Health Eric Sherbet 61 Executive Vice President, General Counsel and Secretary Alistair Grenfell 52 President, Commercial Solutions Bernd Haas 50 Executive Vice President, AI and Technology Solutions James G. Berkshire 52 Executive Vice President, Global Infrastructure and Operations Michael J. Fedock 51 Senior Vice President, Financial Planning and Analysis Ari Bousbib, Director, Chairman and Chief Executive Officer Mr. Bousbib is Chairman and Chief Executive Officer of the Company. He assumed this position in October 2016 following the Merger of Quintiles and IMS Health. From 2010 until the Merger, Mr. Bousbib served as Chairman and CEO of IMS Health. Prior to joining IMS Health, Mr. Bousbib spent 14 years at United Technologies Corporation (“UTC”), an aerospace, defense and building systems company. From 2008 until 2010, he served as President of UTC’s Commercial Companies, with executive leadership responsibilities for the worldwide operations of Otis Elevator Company, Carrier Corporation, UTC Fire & Security and UTC Power Inc. From 2002 until 2008, Mr. Bousbib was President of Otis, and from 2000 to 2002, he served as its Chief Operating Officer. Prior to joining UTC, Mr. Bousbib was a partner at Booz Allen Hamilton. Mr. Bousbib currently serves on the board of directors of The Home Depot, Inc. and is a member of the Harvard Medical School Health Care Policy Advisory Council. Mr. Bousbib holds a Master of Science Degree in Mathematics and Mechanical Engineering from the Ecole Superieure des Travaux Publics, Paris, and an M.B.A. from Columbia University. Ronald E. Bruehlman, Executive Vice President and Chief Financial Officer Mr. Bruehlman was appointed as Executive Vice President and Chief Financial Officer effective August 1, 2020. Mr. Bruehlman previously served as Senior Vice President and Chief Financial Officer of IMS Health from July 2011 until the merger of IMS Health and Quintiles in 2016. Prior to joining IMS Health, Mr. Bruehlman worked for 23 years at UTC, advancing through finance positions of increasing responsibility, culminating in his appointment as Vice President, Business Development, which he held from June 2009 to April 2011, where he led the company’s global strategy and corporate development activities. From June 2005 until May 2008, he was Vice President and Chief Financial Officer of Carrier Corporation. Prior to that, Mr. Bruehlman was Vice President, Financial Planning and Analysis for UTC and also served as Director, Investor Relations of UTC. Mr. Bruehlman currently serves as a director and Chair of the Audit Committee of GoodRx Holdings, Inc. Mr. Bruehlman served as a director and Chair of the Audit Committee to Atotech, Ltd. from 2020 to 2022. He also served as a director of The Connecticut Forum from 2005 to 2015 and served as a director of The New England Air Museum from 2009 through 2013. Mr. Bruehlman holds a Bachelor of Science degree in Economics from the University of Delaware, and an M.B.A. from the University of Chicago Booth School of Business. 117 W. Richard Staub, III, President, Research & Development Solutions Mr. Staub resumed the role of President, Research & Development Solutions on September 25, 2023. From April 2022 through September 2023, Mr. Staub was senior advisor to the Chairman and CEO of IQVIA. Mr. Staub had served as President, Research & Development Solutions from November 2016 to March 2022. Previously, Mr. Staub served as President of Novella Clinical, a Quintiles company, since 2013. Prior to Novella’s 2013 acquisition by Quintiles, Mr. Staub served as both president and CEO of Novella Clinical since 2008. Before joining Novella Clinical in 2004, Mr. Staub was senior vice president of global business development for one of the world’s largest clinical research organizations. Mr. Staub’s career in the pharmaceutical industry began at Zeneca Pharmaceuticals in 1989 where he had progressive responsibilities as a medical and hospital sales representative, cardiovascular portfolio analyst and marketing manager. Mr. Staub has a Bachelor of Arts degree in Economics from the University of North Carolina at Chapel Hill. Bhavik Patel, President, MedTech and Consumer Health Mr. Patel has served as President, MedTech and Consumer Health since December 2025. Prior to that, he served as President, Commercial Solutions from July 2022 to December 2025. Mr. Patel also previously served as Senior Vice President, Global Market Insights and MedTech from September 2018 to July 2022. Prior to that, Mr. Patel held roles of increasing responsibility within IQVIA’s Global Market Insights business. Before joining IQVIA in 2005, Mr. Patel began his career in the healthcare industry at Schwarz Pharma in 2003, where he was responsible for sales to healthcare professionals. Eric Sherbet, Executive Vice President, General Counsel and Secretary Mr. Sherbet has served as our Executive Vice President, General Counsel and Secretary since March 2018. Prior to joining the Company, he served as General Counsel and Secretary at Patheon N.V. from November 2014 until November 2017. Prior to joining Patheon, he was General Counsel and Corporate Secretary at InVentiv Health from April 2011 until October 2014. He also previously served as Vice President, Deputy General Counsel and Corporate Secretary at Foster Wheeler AG and before that, as Vice President, Corporate and Securities Law and Secretary with Avaya, Inc. Mr. Sherbet earned his law degree from New York University School of Law and received his bachelor’s degree in commerce/accounting from University of Virginia. Alistair Grenfell, President, Commercial Solutions Mr. Grenfell has served as President, Commercial Solutions since December 2025. Mr. Grenfell previously served as President, Europe, Middle East, Africa and South Asia Regional Business Unit from January 2020 to December 2025. In addition, Mr. Grenfell led IQVIA’s Global Public Health initiatives during this time. From May 2015 to December 2019, Mr. Grenfell served as President, North Europe, Middle East, Africa and South Asia. Since joining IMS Health, IQVIA’s predecessor company, in 1996, Mr. Grenfell has held sales, client services and business management roles of increasing responsibility in EMEA. Mr. Grenfell holds a Bachelor of Arts degree with honors in Business Economics from Anglia Ruskin University and a Master of Science in Economics and Competition Policy from Bayes Business School, City St. George’s, University of London. Bernd Haas, Executive Vice President, AI and Technology Solutions Mr. Haas has served as Executive Vice President, AI and Technology Solutions since December 2025. Mr. Haas previously served as Senior Vice President, Digital Products & Solutions from January 2024 to December 2025. Mr. Haas has over 20 years of experience in the healthcare and pharmaceutical industry. He joined IQVIA in 2013 and had responsibility for the Technology Solutions business across Europe, Middle East, Africa and South Asia. Before joining IQVIA, Mr. Haas was an associate principal at McKinsey and Company leading the pharma multi-channel marketing group. Prior to McKinsey, he held various roles at Bayer Pharmaceuticals, including country manager Denmark and sales & marketing head, Poland. Mr. Haas holds a master's degree in international business from the University of Bamberg. 118 James G. Berkshire, Executive Vice President, Global Infrastructure and Operations Mr. Berkshire has served as our Executive Vice President, Global Infrastructure and Operations since December 2025. Mr. Berkshire previously served as Executive Vice President, Global Technology and Operations from January 2024 to December 2025. Prior to that, he was Senior Vice President, Business Operations, where he focused on operational excellence, productivity improvements and cost management. Previously, Mr. Berkshire was Vice President, Organizational Effectiveness at IMS Health, IQVIA’s predecessor company. Mr. Berkshire has a Bachelor of Arts degree in economics from Indiana University. Michael J. Fedock, Senior Vice President, Financial Planning and Analysis Mr. Fedock has served as our Senior Vice President, Financial Planning and Analysis since April 2021. From July 2019 to April 2021, Mr. Fedock served as the CFO for the Company’s Research & Development Solutions Business Unit and from May 2016 to July 2019, he served as CFO of IQVIA Laboratories (formally known as Q2 Solutions, a joint venture between the Company and Quest Diagnostics Incorporated and a leading clinical trial laboratory services organization). Prior to joining IQVIA Laboratories, Mr. Fedock spent 13 years with ICON plc where he held various roles of increasing responsibility in both financial and operational leadership positions. Mr. Fedock has a bachelor’s degree in biological sciences from Drexel University and a Master of Business Administration from the University of Baltimore. Item 11. Executive Compensation Compensation The information required by this Item is set forth under the headings “Director Compensation,” “Compensation Discussion and Analysis,” “Leadership Development and Compensation Committee Report,” “Compensation of Named Executive Officers,” and “Other Relevant Information—Compensation Committee Interlocks and Insider Participation” in the Company's 2026 Proxy Statement and is incorporated herein by reference. Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters Information in response to this Item, other than Securities Authorized for Issuance Under Equity Compensation Plans, is set forth in the section entitled “Security Ownership of Certain Beneficial Owners and Management” in the Company’s 2026 Proxy Statement, which information is incorporated herein by reference. 119 Securities Authorized for Issuance Under Equity Compensation Plans The following table provides certain information with respect to all of our equity compensation plans in effect as of December 31, 2025: Equity Compensation Plan Information Plan Category Number of Securities to be issued Upon Exercise of Outstanding Options, Warrants and Rights (a) Weighted Average Exercise Price of Outstanding Options, Warrants and Rights (b) Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (excluding securities reflected in column (a)) (c) Equity compensation plans approved by security holders 6,041,586 (1) $ 173.70 (3) 6,573,173 (4) Equity compensation plans not approved by security holders 26,727 (2) — — Total 6,068,313 $ 173.70 (3) 6,573,173 (1) Consists of: (i) 3,342,758 shares of common stock issuable upon the exercise of outstanding time-based stock options and underlying outstanding time-based SARs; (ii) 1,454,410 shares of common stock issuable in settlement of outstanding restricted stock units awarded; (iii) 1,222,735 shares of common stock issuable in settlement of outstanding performance units awarded; and (iv) 21,683 shares of deferred common stock outstanding under the Director Deferral Plan. (2) Consists of outstanding awards issued to certain executives with supplemental pension benefits in accordance with their individual employment arrangements under the IMS Health DCERP. (3) The weighted-average exercise price includes all outstanding stock options and SARs but does not include restricted stock units, performance units, deferred stock or IMS Health DCERP awards, all of which do not have an exercise price. If restricted stock units, performance units and other awards that constitute “rights” were included in this calculation, treating such awards as having an exercise price of $0, the weighted average exercise price of outstanding options, warrants and rights would be $96.11. (4) Consists of all securities remaining available under our equity compensation plans. All of these shares are available for delivery under stock options, SARs, restricted stock, restricted stock units, performance awards or other forms of equity awards authorized by the plans. Does not include 2,251,704 shares that would have remained available under our Employee Stock Purchase Plan had it not been discontinued as of December 31, 2016. Item 13. Certain Relationships and Related Transactions and Director Independence The information required by this item is set forth under the headings “Corporate Governance,” and “Certain Relationships and Related Party Transactions” in the 2026 Proxy Statement and is incorporated herein by reference. Item 14. Principal Accountant Fees and Services The information required by this item is set forth under the headings “Audit—Fees Paid to Independent Registered Public Accounting Firm” in the 2026 Proxy Statement and is incorporated herein by reference. 120 PART IV Item 15. Exhibits and Financial Statement Schedules (a) The following documents are filed as part of this report: (1) Financial Statements The following consolidated financial statements of IQVIA Holdings Inc. and its subsidiaries, and the independent registered public accounting firm’s report thereon, are included in Part II, Item 8 of this Annual Report: Page Management’s Report on Internal Control over Financial Reporting 67 Report of Independent Registered Public Accounting Firm (PCAOB ID: 238 ) 67 Consolidated Statements of Income 70 Consolidated Statements of Comprehensive Income 71 Consolidated Balance Sheets 72 Consolidated Statements of Cash Flows 73 Consolidated Statements of Stockholders’ Equity 74 Notes to Consolidated Financial Statements 75 (2) Financial Statement Schedules for the Years Ended December 31, 2025, 2024 and 2023 Schedule I—Condensed Financial Information of Registrant (Parent Company Only) 127 Schedule II—Valuation and Qualifying Accounts 131 All other schedules are omitted, since the required information is not applicable or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements and notes thereto. (3) Exhibits The exhibits in the accompanying Exhibit Index preceding the signature page are filed or furnished as a part of this report and are incorporated herein by reference. The Company agrees to furnish to the SEC, upon request, copies of any long-term debt instruments that authorize an amount of securities constituting 10% or less of the total assets of IQVIA Holdings Inc. and its subsidiaries on a consolidated basis. 121 EXHIBIT INDEX Incorporated by Reference Exhibit Number Exhibit Description Filed Herewith Form File No. Exhibit Filing Date 3.1 Amended and Restated Certificate of Incorporation of IQVIA Holdings Inc., effective April 24, 20 2 5 . 8-K 001-35907 3.1 April 24, 2025 3.2 Amended and Restated Bylaws of IQVIA Holdings Inc., effective April 18, 2023. 8-K 001-35907 3.2 April 18, 2023 4.1 Description of the Company's Securities . X 4.2 Indenture, dated as of September 28, 2016, among Quintiles IMS Incorporated, the Guarantors listed therein and U.S. Bank National Association, as Trustee. 8-K 001-35907 4.1 October 3, 2016 4.3 Indenture, dated May 10, 2019, among IQVIA Inc., as Issuer, U.S. Bank National Association, as trustee of the Notes and certain subsidiaries of the Issuer, as guarantors Association, as trustee of the Notes and certain subsidiaries of the Issuer, as guarantors. 8-K 001-35907 4.1 May 10, 2019 4.4 Indenture, dated August 13, 2019, among IQVIA Inc., as Issuer, U.S. Bank National Association, as trustee of the Notes and certain subsidiaries of the Issuer, as guarantors Association, as trustee of the Notes and certain subsidiaries of the Issuer, as guarantors. 8-K 001-35907 4.1 August 13, 2019 4.5 Indenture, dated June 24, 2020, among IQVIA Inc., as Issuer, U.S. Bank National Association, as trustee of the Notes and certain subsidiaries of the Issuer, as guarantors. 8-K 001-35907 4.1 June 24, 2020 4.6 Indenture, dated March 3, 2021, among IQVIA Inc., as Issuer, U.S. Bank National Association, as trustee of the Notes and certain subsidiaries of the Issuer, as guarantors. 8-K 001-35907 4.1 March 3, 2021 4.7 Indenture, dated May 23, 2023, among IQVIA Inc., as Issuer, U.S. Bank Trust Company, National Association, as Trustee of the 6.500% Senior Notes due 2030 and certain subsidiaries of the Issuer as guarantors. 8-K 001-35907 4.2 May 23, 2023 4.8 Amended and Restated Indenture, dated December 19, 2023, among IQVIA Inc., as Issuer, U.S. Bank Trust Company, National Association, as trustee of the 5.700% Senior Secured Notes due 2028 and the Company and certain subsidiaries of the Issuer as guarantors. S-4 001-35907 4.8 January 5, 2024 4.9 Supplemental Indenture, dated as of June 27, 2024, among the subsidiary guarantors named on the signature pages thereto and U.S. Bank Trust Company, National Association, as trustee of the 5.700% Senior Secured Notes due 2028. 10-Q 001-35907 4.1 July 22, 2024 4.10 Supplemental Indenture, dated as of December 5, 2025, among the subsidiary guarantors named on the signature pages thereto and U.S. Bank Trust Company, National Association, as trustee of the 5.700% Senior Secured Notes due 2028. X 4.11 Amended and Restated Indenture, dated December 19, 2023, among IQVIA Inc., as Issuer, U.S. Bank Trust Company, National Association, as trustee of the 6.250% Senior Secured Notes due 2029 and the Company and certain subsidiaries of the Issuer as guarantors. S-4 001-35907 4.9 January 5, 2024 4.12 Supplemental Indenture, dated as of June 27, 2024, among the subsidiary guarantors named on the signature pages thereto and U.S. Bank Trust Company, National Association, as trustee of the 6.250% Senior Secured Notes due 2029. 10-Q 001-35907 4.2 July 22, 2024 4.13 Supplemental Indenture, dated as of December 5, 2025, among the subsidiary guarantors named on the signature pages thereto and U.S. Bank Trust Company, National Association, as trustee of the 6.250% Senior Secured Notes due 2029. X 4.14 Indenture, dated June 4, 2025, among IQVIA Inc., as Issuer, U.S. Bank Trust Company, National Association, as trustee of the 6.250% Senior Notes due 2032 and certain subsidiaries of the Issuer as guarantors. 8-K 001-35907 4.1 June 4, 2025 122 10.1 Fifth Amended and Restated Credit Agreement, dated as of August 25, 2021, by and among IQVIA Inc., IQVIA RDS Inc., IQVIA AG, IQVIA Solutions Japan K.K., IQVIA Holdings Inc., the Guarantors party thereto and the Lenders party thereto (Annex A to Exhibit 10.1 filed August 25, 2021). 8-K 001-35907 10.1 August 25, 2021 10.2 Amendment No. 1 to Fifth Amended and Restated Credit Agreement, dated June 16, 2022, among IQVIA Inc., IQVIA Holdings Inc., IQVIA RDS Inc. the other guarantors party thereto, Bank of America, N.A. as administrative agent and as collateral agent, and the Lenders party thereto. 8-K 001-35907 10.1 June 16, 2022 10.3 Amendment No. 2 to Fifth Amended and Restated Credit Agreement, dated April 17, 2023, among IQVIA Inc., IQVIA Holdings Inc., IQVIA RDS Inc., IQVIA AG, IQVIA Japan K.K., the other guarantors party thereto, Bank of America, N.A. as administrative agent and as collateral agent, and the Lenders party thereto. 8-K 001-35907 10.1 April 18, 2023 10.4 Amendment No. 3 to Fifth Amended and Restated Credit Agreement, dated November 28, 2023, among IQVIA Inc., IQVIA Holdings Inc., IQVIA RDS Inc., IQVIA AG, IQVIA Solutions Japan LLC, the other guarantors party thereto, Bank of America, N.A. as administrative agent and as collateral agent, and the Lenders party thereto. 8-K 001-35907 10.1 November 23, 2023 10.5 Amendment No. 4 to Fifth Amended and Restated Credit Agreement, dated March 10, 2025, among IQVIA Inc., IQVIA Holdings Inc., IQVIA RDS Inc., the other guarantors party thereto, Bank of America, N.A. as administrative agent and as collateral agent, and the Lenders party thereto. 8-K 001-35907 10.1 March 10, 2025 10.6 Amendment No. 5 to Fifth Amended and Restated Credit Agreement, dated December 9, 2025, among IQVIA Inc., IQVIA Holdings Inc., IQVIA RDS Inc., IQVIA AG, IQVIA Solutions Japan LLC, the other guarantors party thereto, Bank of America, N.A. as administrative agent and as collateral agent, and the Lenders party thereto. 8-K 001-35907 10.1 December 9, 2025 10.7 Amended and Restated Pledge and Security Agreement, dated as of March 17, 2014, among Healthcare Technology Intermediate Holdings, Inc., IMS Health Incorporated, each of the grantors party thereto, and Bank of America, N.A., as Administrative Agent. IMS Health S-1/A 333-193159 10.33 March 24, 2014 10.8 U.S. Guaranty, dated as of March 17, 2014, among Healthcare Technology Intermediate Holdings, Inc., as Holdings, IMS Health Incorporated, as Parent Borrower, the other Guarantors party thereto from time to time, and Bank of America, N.A., as Administrative Agent. IMS Health S-1/A 333-193159 10.34 March 24, 2014 10.9† Form of Director Indemnification Agreement X 10.10† Form of Confidentiality and Restrictive Covenants Agreement . 10-K 001-35907 10.9 February 15, 2024 10.11† Work Product Assignment Agreement . 10-K 001-35907 10.10 February 15, 2024 10.12† Quintiles Transnational Holdings Inc. 2013 Stock Incentive Plan. S-1/A 333-186708 10.22 April 19, 2013 10.13† Form of Award Agreement Awarding Stock Appreciation Rights under the Quintiles IMS Holdings, Inc. 2013 Stock Incentive Plan effective February 2017. 10-K 001-35907 10.41 February 16, 2017 10.14† Quintiles IMS Holdings, Inc. Defined Contribution Executive Retirement Plan . 8-K 001-35907 10.7 October 3, 2016 10.15† IMS Health Incorporated Defined Contribution Executive Retirement Plan, as amended and restated. IMS Health S-1 333-193159 10.10 January 2, 2014 10.16† First Amendment to the IMS Health Incorporated Retirement Excess Plan, dated March 17, 2009. IMS Health S-1 333-193159 10.12 January 2, 2014 10.17† Second Amendment to the IMS Health Incorporated Retirement Excess Plan, dated December 8, 2009. IMS Health S-1 333-193159 10.13 January 2, 2014 123 10.18† Third Amendment to the IMS Health Incorporated Retirement Excess Plan, dated April 5, 2011 . IMS Health S-1 333-193159 10.14 January 2, 2014 10.19† Fourth Amendment to the IMS Health Incorporated Retirement Excess Plan (effective May 3, 2016). IMS Health 10-Q 001-36381 10.3 July 28, 2016 10.20† IMS Health Incorporated Retirement Plan, as amended and restated effective January 1, 2020 . 10-K 001-35907 10.19 February 15, 2024 10.21† Quintiles IMS Holdings, Inc. 2014 Incentive and Stock Award Plan. 8-K 001-35907 10.6 October 3, 2016 10.22† Form of IMS Stock Appreciation Rights Agreement under the 2014 Incentive and Stock Award Plan. IMS Health 8-K 001-36381 10.1 February 10, 2015 10.23† IQVIA Holdings Inc. 2017 Incentive Stock Award Plan (f/k/a Quintiles IMS Holdings, Inc. 2017 Incentive and Stock Award Plan). DEF 14A 001-35907 Appendix B February 22, 2017 10.24† Form of Award Agreement Awarding Stock Appreciation Rights under the Quintiles IMS Holdings, Inc. 2017 Incentive and Stock Award Plan effective April 2017. 10-Q 001-35907 10.8 May 8, 2017 10.25† Form of Award Agreement Awarding Performance Shares under the Quintiles IMS Holdings, Inc. 2017 Incentive and Stock Award Plan effective April 2017. 10-Q 001-35907 10.9 May 8, 2017 10.26† Form of Award Agreement Awarding Restricted Stock Units under the Quintiles IMS Holdings, Inc. 2017 Incentive and Stock Award Plan effective April 2017. 10-Q 001-35907 10.10 May 8, 2017 10.27† IQVIA Inc. Employee Protection Plan and Summary Plan Description, as amended and restated effective July 1, 2023. 10-Q 001-35907 10.1 August 1, 2023 10.28† IQVIA Savings Equalization Plan, effective January 1, 2018. 10-K 001-35907 10.27 February 15, 2024 10.29† IQVIA Elective Deferred Compensation Plan, as amended and restated. 10-K 001-35907 10.28 February 15, 2024 10.30† IQVIA Holdings Inc. Non-Employee Director Deferral Plan, effective January 1, 2017 (amended November 9, 2023). 10-K 001-35907 10.29 February 15, 2024 10.31† Amended and Restated Employment Agreement between IQVIA Holdings Inc. and Ari Bousbib, dated February 18, 2019. 10-K 001-35907 10.60 February 19, 2019 10.32† Stock Appreciation Rights Agreement between IMS Health Holdings, Inc. and Ari Bousbib, dated February 10, 2015. IMS Health 10-K 001-36381 10.34 February 19, 2016 10.33† Amendment No. 1, dated December 31, 2015, to Stock Appreciation Rights Agreement between IMS Health Holdings, Inc. and Ari Bousbib dated February 10, 2015. IMS Health 10-K 001-36381 10.35 February 19, 2016 10.34† Letter Agreement between the Company and Eric Sherbet, effective on March 1, 2018 . 10-K 001-35907 10.72 February 19, 2019 10.35† Letter Agreement between the Company and Ronald Bruehlman, effective on August 1, 2020. 10-Q 001-35907 10.1 October 22, 2020 10.36† Letter Agreement between the Company and W. Richard Staub, effective on September 25, 2023. 10-K 001-35907 10.35 February 15, 2024 10.37† Employment Agreement between IQVIA AG and Bhavik Patel, effective as of August 7, 2018, as amended on August 9, 2022 and August 1, 2023. 10-K 001-35907 10.36 February 13, 2025 10.38† Employment Agreement between IMS Health Limited and Alistair Grenfell, effective as of July 15, 2003, as amended January 13, 2026. X 19.1 Securities Trading Policy X 21.1 List of Subsidiaries of IQVIA Holdings Inc. X 22.1 List of Subsidiary Guarantors and Affiliates who Collateralize the Company’s Securities . X 23.1 Consent of PricewaterhouseCoopers LLP. X 31.1 Certification of Chief Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 124 31.2 Certification of Executive Vice President and Chief Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 32.1 Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X 32.2 Certification of Executive Vice President and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X 97.1† Restatement Recovery Policy, dated November 9, 2023. 10-K 001-35907 97.1 February 15, 2024 101 Interactive Data Files Pursuant to Rule 405 of Regulation S-T: (i) Consolidated Statements of Income, (ii) Consolidated Statements of Comprehensive Income, (iii) Consolidated Balance Sheets, (iv) Consolidated Statements of Cash Flows, (v) Notes to Consolidated Financial Statements and (vi) Notes to Consolidated Financial Statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. X 104 Cover Page Interactive Data File. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. X † Indicates management contract or compensatory plan or arrangement. Item 16. Form 10-K Summary None. SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IQVIA HOLDINGS INC. By: /s/ Ronald E. Bruehlman Name: Ronald E. Bruehlman Title: Executive Vice President and Chief Financial Officer Date: February 17, 2026 Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated. 125 Signature Title Date /s/ Ari Bousbib Chairman and Chief Executive Officer; Director February 17, 2026 Ari Bousbib (Principal Executive Officer) /s/ Ronald E. Bruehlman Executive Vice President and Chief Financial Officer February 17, 2026 Ronald E. Bruehlman (Principal Financial Officer) /s/ Keriann Cherofsky Senior Vice President, Chief Accounting Officer and Corporate Controller February 17, 2026 Keriann Cherofsky (Principal Accounting Officer) /s/ Carol J. Burt Director February 17, 2026 Carol J. Burt /s/ John G. Danhakl Director February 17, 2026 John G. Danhakl /s/ James A. Fasano Director February 17, 2026 James A. Fasano /s/ Colleen A. Goggins Director February 17, 2026 Colleen A. Goggins /s/ William G. Kaelin Jr., M.D. Director February 17, 2026 William G. Kaelin Jr., M.D. /s/ John M. Leonard, M.D. Director February 17, 2026 John M. Leonard, M.D. /s/ Leslie Wims Morris Director February 17, 2026 Leslie Wims Morris /s/ Todd B. Sisitsky Director February 17, 2026 Todd B. Sisitsky /s/ Sheila A. Stamps Director February 17, 2026 Sheila A. Stamps 126 (2) Financial Statement Schedules Schedule I—Condensed Financial Information of Registrant IQVIA HOLDINGS INC. (PARENT COMPANY ONLY) CONDENSED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Year Ended December 31, (in millions) 2025 2024 2023 Equity in earnings of subsidiary, net of tax $ 1,360 $ 1,373 $ 1,358 Net income 1,360 1,373 1,358 Equity in other comprehensive income (loss) of subsidiary, net of tax 95 ( 171 ) ( 140 ) Comprehensive income $ 1,455 $ 1,202 $ 1,218 The accompanying note is an integral part of these condensed financial statements. 127 IQVIA HOLDINGS INC. (PARENT COMPANY ONLY) CONDENSED BALANCE SHEETS December 31, (in millions, except per share data) 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 1 $ — Total current assets 1 — Investment in subsidiary 9,667 9,667 Total assets $ 9,668 $ 9,667 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 8 $ 9 Total current liabilities 8 9 Investment in subsidiary 3,154 3,588 Payable to subsidiary 3 3 Total liabilities 3,165 3,600 Commitments and contingencies Stockholders’ equity: Common stock and additional paid-in capital, 400.0 shares authorized as of December 31, 2025 and 2024, $ 0.01 par value, 259.1 shares issued and 169.6 shares outstanding as of December 31, 2025; 258.2 shares issued and 176.1 shares outstanding as of December 31, 2024 11,378 11,143 Retained earnings 7,425 6,065 Treasury stock, at cost, 89.5 and 82.1 shares as of December 31, 2025 and 2024, respectively ( 11,357 ) ( 10,103 ) Accumulated other comprehensive loss ( 943 ) ( 1,038 ) Total stockholders’ equity 6,503 6,067 Total liabilities and stockholders’ equity $ 9,668 $ 9,667 The accompanying note is an integral part of these condensed financial statements. 128 IQVIA HOLDINGS INC. (PARENT COMPANY ONLY) CONDENSED STATEMENTS OF CASH FLOWS Year Ended December 31, (in millions) 2025 2024 2023 Operating activities: Net Income $ 1,360 $ 1,373 $ 1,358 Adjustments to reconcile net income to cash provided by operating activities: Equity in earnings of subsidiary ( 1,360 ) ( 1,373 ) ( 1,358 ) Change in operating assets and liabilities: Other operating assets and liabilities ( 1 ) ( 11 ) — Net cash from operating activities ( 1 ) ( 11 ) — Investing activities: Dividends received 1,323 1,423 1,052 Net cash from investing activities 1,323 1,423 1,052 Financing activities: Payments related to employee stock incentive plans, net ( 67 ) ( 64 ) ( 61 ) Repurchase of common stock ( 1,244 ) ( 1,350 ) ( 992 ) Intercompany with subsidiary — — 1 Other ( 10 ) — — Net cash from financing activities ( 1,321 ) ( 1,414 ) ( 1,052 ) Change in cash and cash equivalents 1 ( 2 ) — Cash and cash equivalents at beginning of period — 2 2 Cash and cash equivalents at end of period $ 1 $ — $ 2 The accompanying note is an integral part of these condensed financial statements. 129 IQVIA HOLDINGS INC. (PARENT COMPANY ONLY) NOTES TO CONDENSED FINANCIAL INFORMATION The condensed parent company financial statements have been prepared in accordance with Rule 12-04, Schedule I of Regulation S-X as the restricted net assets of IQVIA Holdings Inc.’s (the “Company”) wholly owned subsidiary, IQVIA Incorporated, exceed 25 % of the consolidated net assets of the Company. These condensed parent company financial statements are not the general-purpose financial statements of the reporting entity. The ability of IQVIA Incorporated to pay dividends may be limited due to the restrictive covenants in the agreements governing its credit arrangements. These condensed parent company financial statements include the accounts of IQVIA Holdings Inc. on a standalone basis (the “Parent”) and the equity method of accounting is used to reflect ownership interest in its subsidiary. Refer to the consolidated financial statements and notes presented elsewhere herein for additional information and disclosures with respect to these financial statements. Below is a summary of the dividends paid to the Parent by IQVIA Incorporated in the years ended December 31, 2025, 2024 and 2023: (in millions) Amount Paid in December 2025 $ 92 Paid in November 2025 120 Paid in July 2025 32 Paid in June 2025 165 Paid in May 2025 289 Paid in April 2025 214 Paid in March 2025 375 Paid in February 2025 36 Total paid in 2025 $ 1,323 Paid in December 2024 $ 200 Paid in November 2024 952 Paid in October 2024 11 Paid in September 2024 201 Paid in August 2024 1 Paid in February 2024 58 Total paid in 2024 $ 1,423 Paid in November 2023 $ 232 Paid in September 2023 55 Paid in August 2023 89 Paid in May 2023 490 Paid in March 2023 130 Paid in February 2023 56 Total paid in 2023 $ 1,052 130 Schedule II—Valuation and Qualifying Accounts Deferred Tax Asset Valuation Allowance Additions (in millions) Balance at Beginning of Year Charged to Expenses Charged to Other Accounts(a) Additions (Deductions) (b) Balance at End of Year December 31, 2025 $ 196 $ ( 8 ) $ — $ 18 $ 206 December 31, 2024 $ 166 $ ( 12 ) $ — $ 42 $ 196 December 31, 2023 $ 257 $ ( 99 ) $ — $ 8 $ 166 (a) Recorded through purchase accounting transactions. (b) Impact of additions or reductions recorded to expense and translation adjustments. 131